Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to -$23.2 million.

  • Tg Therapeutics' Free Cash Flow fell 8998.28% to -$23.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.2 million, marking a year-over-year decrease of 14987.9%. This contributed to the annual value of -$40.6 million for FY2024, which is 2912.49% down from last year.
  • As of Q3 2025, Tg Therapeutics' Free Cash Flow stood at -$23.2 million, which was down 8998.28% from $7.4 million recorded in Q2 2025.
  • Tg Therapeutics' Free Cash Flow's 5-year high stood at $83.7 million during Q3 2023, with a 5-year trough of -$87.0 million in Q4 2021.
  • Moreover, its 5-year median value for Free Cash Flow was -$28.7 million (2025), whereas its average is -$31.0 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first soared by 34262.73% in 2023, then tumbled by 25018.89% in 2025.
  • Over the past 5 years, Tg Therapeutics' Free Cash Flow (Quarter) stood at -$87.0 million in 2021, then soared by 72.56% to -$23.9 million in 2022, then surged by 44.67% to -$13.2 million in 2023, then plummeted by 94.26% to -$25.7 million in 2024, then rose by 9.47% to -$23.2 million in 2025.
  • Its Free Cash Flow stands at -$23.2 million for Q3 2025, versus $7.4 million for Q2 2025 and -$28.7 million for Q1 2025.